DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/42xh5s/china) has announced the addition of the "China Prescription Drug - Blood Drug Sales Report 2012" report to their offering.
China Prescription Drug (CPD) reports are designed to help you understand the size and competitive landscape of various drug markets in China.
This CPD report provides data for the Chinese Blood Products Drug Market, including:
Market size
Sales and shares of key companies
Sales of key blood products drugs and market shares by manufacturer
Blood products drug prices
Blood products drugs on the national reimbursement list
This CPD report provides invaluable information for all levels of decision makers in the following areas:
New product development
Marketing
Strategic planning
Forecasting
Methodology:
- Extensive primary research including quarterly surveys of 372 hospitals
- Strategic and geographic sampling method designed for optimal representation of the 13,000+ Chinese public hospitals that account for 91% of the total market
- Therapeutic areas categorized using WHO ATC codes
- Total national sales estimates extrapolated using sample data, statistical models, and in-house expert knowledge of drug markets
- Data validation with key manufacturers
- Data validation via exclusive licensing arrangement with the Chinese State Food and Drug Administration (SFDA)
- Data validation using extensive secondary research efforts
Companies Mentioned
- Baxter
- Jiangsu Huarui
- Sichuan Kelun
- Fresenius Kabi
- Aventis Behring
- Otsuka
- Beijing Shuanghe
- B. Braun, Melsungen
- Shandong Lukang Chenxin
- Shandong Huaren
- Nutricia Wuxi
- Harbin Sanlian
- Hualan Shengwu
- Hainan Lingkang
- FERRING AB(SW)
- Sichuan Yuanda Shuyang
- Jiangsu Zhengda Fenghai
- Chengdu Rongsheng
- Chongqing Xinan
- Guangzhou Baiyunshan Qiaoguang
For more information visit http://www.researchandmarkets.com/research/42xh5s/china